The Insides News- The Insides Neo - fistuloclysis, distal feeding, best, alternative to parenteral nutrition, fistula, ostomy, ileostomy, chyme, enteral, oral nutrition, enteromate, intestinal failure, colon cancer, bowel cancer, gut cancer, ostomy appliance, high output, chyme, dehydration, defunctioned, ileus, lars, microbiome, lower interior resection syndrome, incontinent, incontinence, gut health, reversal surgery
The Insides Company and Paripro Sign Distribution Agreement For Chyme Reinfusion‍

The Insides Company and Paripro Sign Distribution Agreement For Chyme Reinfusion‍

July 3, 2023

Press Release

Source:The Insides Company Limited

On:03 July 2023

Organisations:The Insides Company Limited, Paripro GmbH

The Insides Company, a medical technology company focused on the development and commercialisation of novel chyme reinfusion therapy (CRT) devices for the treatment of intestinal failure, today announces Paripro GmbH as distributor for Switzerland. Heinz Drurer, Managing Director of Paripro remarked:“Paripro has been active in the medical industry for many years, distributing high-quality and unique products providing the best solutions for the requirements of doctors and patients. Therefore, we are very proud to offer The Insides System to patients in Switzerland”. Garth Sutherland, CEO of The Insides Co., said “The Insides are proud to introduce Paripro as the sole distributor of our purpose-built chyme reinfusion in Switzerland. Paripro bring a strong network in the colorectal field, having supplied, and supported specialised surgical devices such as sacral neuromodulation devices to Swiss surgeons for many years. With several leading hospitals in Switzerland already prescribing our devices, and with several Swiss insurers now funding them for their members, we are really looking forward to working with the excellent team at Paripro to offer chyme reinfusion nationwide.”

About Type II Intestinal Failure and Chyme Reinfusion Therapy

Type II intestinal failure is the inability of the gut to absorb necessary water, macronutrients, micronutrients, and electrolytes to sufficiently sustain life without intravenous supplementation or replacement. This can be due to malabsorption (small bowel mucosal disease), surgical resection (short bowel syndrome), fistulae, dysmotility, or mechanical obstruction. Under the standard care pathway, patients recovering from colorectal surgery often have an enterostomy created to divert intestinal contents (chyme) away from the surgical site as it heals. The enterostomy is typically left open for 6-12 months, and during this time the chyme that is collected is disposed of, which can result in intestinal failure and other complications. The Insides System is a purpose-built medical device for performing chyme reinfusion therapy. Chyme reinfusion is a practice in the management of patients with high-output enterocutaneous fistulas, and high-output enterostomies. It enables patients to re-commence oral feeding, resulting in significant clinical benefits, health economic benefits, and improvements in patient quality of life.

About Paripro

Paripro GmbH, a privately owned Company in Switzerland, is a leading importer and distributor of innovative medical devices and disposable products in Switzerland. The company is focusing its services on specialty fields like Gastroenterology, Coloproctology, Neuro-Urology, and Visceral-Surgery. Paripro is ISO 9001 :2015 certified and a member of the Swiss MedTech industrial association.

About The Insides Company

The Insides Company has commercialised 30 years of clinical experience in gut nutrition into breakthrough medical devices. The Insides Company’s mission is to provide universal access to chyme reinfusion therapy through revolutionary products and education to establish a new standard of care.


The Insides Company

Anthony Fife, Commercial Advisor

Phone:+44 20 3389 6331

Paripro GmbH

Florian Wagner, CEO


Choose Your Language

Selecting language below will change the language for